TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Artelo Biosciences ( (ARTL) ) has issued an announcement.
On November 10, 2025, Artelo Biosciences, Inc. announced changes to its bylaws, impacting the governance structure of the company. The amendments include the elimination of stockholders’ rights to fill board vacancies and the election of directors by a plurality of votes at stockholder meetings, potentially affecting shareholder influence and corporate governance dynamics.
The most recent analyst rating on (ARTL) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Artelo Biosciences stock, see the ARTL Stock Forecast page.
Spark’s Take on ARTL Stock
According to Spark, TipRanks’ AI Analyst, ARTL is a Underperform.
Artelo Biosciences faces substantial financial hurdles with no revenue and continuous losses, heavily impacting its overall score. Technical indicators do not show a strong recovery trend, and the lack of new guidance from earnings calls further adds uncertainty. Valuation metrics are unfavorable due to negative earnings, making the stock less appealing to investors.
To see Spark’s full report on ARTL stock, click here.
More about Artelo Biosciences
Average Trading Volume: 234,474
Technical Sentiment Signal: Sell
Current Market Cap: $2.06M
See more data about ARTL stock on TipRanks’ Stock Analysis page.